Callahan Advisors LLC Acquires Shares of 866 Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Callahan Advisors LLC acquired a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 866 shares of the biopharmaceutical company’s stock, valued at approximately $617,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Mizuho Securities USA LLC increased its holdings in Regeneron Pharmaceuticals by 625.5% in the third quarter. Mizuho Securities USA LLC now owns 59,341 shares of the biopharmaceutical company’s stock valued at $62,382,000 after buying an additional 51,162 shares in the last quarter. Principal Financial Group Inc. increased its holdings in Regeneron Pharmaceuticals by 1.7% in the third quarter. Principal Financial Group Inc. now owns 173,092 shares of the biopharmaceutical company’s stock valued at $181,961,000 after buying an additional 2,828 shares in the last quarter. Simplify Asset Management Inc. increased its holdings in Regeneron Pharmaceuticals by 50.8% in the third quarter. Simplify Asset Management Inc. now owns 9,591 shares of the biopharmaceutical company’s stock valued at $10,082,000 after buying an additional 3,231 shares in the last quarter. Golden State Equity Partners increased its holdings in Regeneron Pharmaceuticals by 1,479.1% in the fourth quarter. Golden State Equity Partners now owns 1,358 shares of the biopharmaceutical company’s stock valued at $967,000 after buying an additional 1,272 shares in the last quarter. Finally, Catalytic Wealth RIA LLC purchased a new position in Regeneron Pharmaceuticals in the third quarter valued at $1,334,000. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently issued reports on REGN. Citigroup dropped their target price on shares of Regeneron Pharmaceuticals from $795.00 to $750.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 28th. Bernstein Bank dropped their target price on shares of Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a research report on Tuesday, February 4th. Leerink Partners upgraded shares of Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating and lifted their target price for the company from $762.00 to $834.00 in a research report on Wednesday, February 5th. Truist Financial dropped their target price on shares of Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a “buy” rating on the stock in a research report on Wednesday, January 8th. Finally, Oppenheimer dropped their target price on shares of Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating on the stock in a research report on Wednesday, November 6th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have issued a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $973.13.

Regeneron Pharmaceuticals Price Performance

Regeneron Pharmaceuticals stock opened at $680.00 on Wednesday. The company’s 50 day simple moving average is $702.67 and its 200-day simple moving average is $889.08. The company has a market capitalization of $74.34 billion, a price-to-earnings ratio of 17.76, a price-to-earnings-growth ratio of 2.26 and a beta of 0.08. Regeneron Pharmaceuticals, Inc. has a 1 year low of $642.00 and a 1 year high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.95 and a current ratio of 4.73.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $11.21 by $0.86. The business had revenue of $3.79 billion for the quarter, compared to the consensus estimate of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The business’s revenue was up 10.3% on a year-over-year basis. During the same period in the previous year, the firm earned $11.86 EPS. As a group, equities research analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th will be paid a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.52%. The ex-dividend date is Thursday, February 20th.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.